Treatment with peginterferon alfa-2a (40KD) (PEGASYS®) results in improved rates of response compared to conventional interferon in patients with HBEAG positive chronic hepatitis B harboring HBV genotypes B or ‘difficult-to-treat’ genotype C
W.G.E. Cooksley, M.-Y. Lai, T. Piratvisuth, Y.-J. Wang, V. Mahachai, Y.-C. Chao, T. Tanwandee, A. Chutaputti, W.-Y. Chang, F.E. Zahm, N. PluckVolume:
38
Year:
2003
Language:
english
DOI:
10.1016/s0168-8278(03)80483-x
File:
PDF, 135 KB
english, 2003